Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company EnGeneIC Ltd.
DescriptionEGFR-targeting, EnGeneIC delivery vehicle (EDV) nanocells packaged with miR-16 microRNAs
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPhase I
Standard IndicationMesothelioma
Indication DetailsTreat malignant pleural mesothelioma (MPM)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today